NO20082536L - Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser - Google Patents

Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser

Info

Publication number
NO20082536L
NO20082536L NO20082536A NO20082536A NO20082536L NO 20082536 L NO20082536 L NO 20082536L NO 20082536 A NO20082536 A NO 20082536A NO 20082536 A NO20082536 A NO 20082536A NO 20082536 L NO20082536 L NO 20082536L
Authority
NO
Norway
Prior art keywords
ckd
individuals
treatment
kidney disease
chronic kidney
Prior art date
Application number
NO20082536A
Other languages
English (en)
Norwegian (no)
Inventor
Raymond Dennis Pratt
Isobel Webster
Stephen Damment
Original Assignee
Shire Internat Licensing Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37114439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082536(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Internat Licensing Bv filed Critical Shire Internat Licensing Bv
Publication of NO20082536L publication Critical patent/NO20082536L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20082536A 2005-11-09 2008-06-06 Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser NO20082536L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/272,563 US20070104799A1 (en) 2005-11-09 2005-11-09 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
PCT/US2006/060598 WO2007056721A2 (en) 2005-11-09 2006-11-07 Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds

Publications (1)

Publication Number Publication Date
NO20082536L true NO20082536L (no) 2008-07-28

Family

ID=37114439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082536A NO20082536L (no) 2005-11-09 2008-06-06 Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser

Country Status (25)

Country Link
US (1) US20070104799A1 (pl)
EP (1) EP1785142B1 (pl)
JP (1) JP2009514986A (pl)
KR (1) KR101318067B1 (pl)
CN (1) CN101304753B (pl)
AR (1) AR057876A1 (pl)
AT (1) ATE492284T1 (pl)
AU (1) AU2006311286B2 (pl)
BR (1) BRPI0619667A2 (pl)
CA (1) CA2629036C (pl)
CY (1) CY1111609T1 (pl)
DE (1) DE602006019043D1 (pl)
DK (1) DK1785142T3 (pl)
EA (1) EA015171B1 (pl)
ES (1) ES2362201T3 (pl)
IL (1) IL190860A0 (pl)
MY (1) MY147391A (pl)
NO (1) NO20082536L (pl)
NZ (1) NZ567519A (pl)
PL (1) PL1785142T3 (pl)
PT (1) PT1785142E (pl)
SI (1) SI1785142T1 (pl)
TW (1) TWI388329B (pl)
WO (1) WO2007056721A2 (pl)
ZA (1) ZA200804853B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2407993T3 (es) * 2009-05-15 2013-06-17 Natco Pharma Limited Procedimiento para la preparación de carbonato de lantano dihidrato
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
CN103120654A (zh) * 2012-02-23 2013-05-29 南京卡文迪许生物工程技术有限公司 醋酸镧或其水合物治疗血磷酸盐过多症的用途
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
CN103127042A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
CN103127043A (zh) * 2013-03-07 2013-06-05 尹颖 一种稳定高效的降磷组合物
US20220079891A1 (en) * 2019-01-04 2022-03-17 L. J. Schurgers Combination therapy of phosphate binders and vitamin k
CN111620363A (zh) * 2020-06-13 2020-09-04 南京卡文迪许生物工程技术有限公司 一种四水合碳酸镧的制备方法及其产品
CN111686008A (zh) * 2020-07-20 2020-09-22 温州海鹤药业有限公司 一种混煎中药去磷工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2117351C (en) * 1992-01-13 1998-03-03 Julian Belknap Lo Preparation of tablets of increased strength
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
KR100956013B1 (ko) * 2001-04-23 2010-05-06 샤이어 인터내쇼날 라이센싱 비.브이. 희토류 화합물을 포함하는 신장 결석 질환 치료용 약제학적 조성물
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EP1660104B1 (en) * 2003-08-26 2010-03-10 Shire Holdings AG Pharmaceutical formulation comprising lanthanum compounds
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
KR20070054191A (ko) * 2004-07-27 2007-05-28 샤이어 파마세우티컬, 인크. 란탄 하이드록시 카보네이트를 이용한 고인산증 치료 방법
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
AU2006227429A1 (en) * 2005-03-17 2006-09-28 Amgen Inc. Methods of decreasing calcification

Also Published As

Publication number Publication date
EP1785142B1 (en) 2010-12-22
NZ567519A (en) 2011-04-29
AR057876A1 (es) 2007-12-26
KR20080071175A (ko) 2008-08-01
EP1785142A1 (en) 2007-05-16
TW200727905A (en) 2007-08-01
DK1785142T3 (da) 2011-03-14
ATE492284T1 (de) 2011-01-15
WO2007056721A3 (en) 2007-10-25
US20070104799A1 (en) 2007-05-10
AU2006311286B2 (en) 2012-08-23
CA2629036A1 (en) 2007-05-18
AU2006311286A1 (en) 2007-05-18
ES2362201T3 (es) 2011-06-29
BRPI0619667A2 (pt) 2011-10-11
CN101304753B (zh) 2012-12-12
EA200801274A1 (ru) 2008-10-30
DE602006019043D1 (de) 2011-02-03
SI1785142T1 (sl) 2011-07-29
ZA200804853B (en) 2014-01-29
IL190860A0 (en) 2008-11-03
EA015171B1 (ru) 2011-06-30
HK1102545A1 (en) 2007-11-30
MY147391A (en) 2012-11-30
JP2009514986A (ja) 2009-04-09
CN101304753A (zh) 2008-11-12
CY1111609T1 (el) 2015-10-07
PT1785142E (pt) 2011-03-23
CA2629036C (en) 2014-07-22
PL1785142T3 (pl) 2011-07-29
TWI388329B (zh) 2013-03-11
WO2007056721A2 (en) 2007-05-18
KR101318067B1 (ko) 2013-10-15

Similar Documents

Publication Publication Date Title
NO20082536L (no) Behandling av kronisk nyresykdom(CKD)individer ved bruk av lantanforbindelser
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20070597L (no) Medikamtenter for a behandle kronisk respiratorisk sykdom.
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
EA200870385A1 (ru) Ингибирование токсичности альфа-синуклеина
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
CY1111799T1 (el) Καινουργιες μεθοδοι
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
BRPI0618239A8 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusicos
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BRPI0920605A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para o tratamento ou profilaxia de infecção pelo hiv ou para o tratamento, profilaxia, ou retardo no início ou progressão da aids em um paciente em necessidade deste.
BRPI0513603A (pt) uso de hidroxicarbonato de lantánio e composição farmacêutica
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
DK2388315T3 (da) Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
MX2010000120A (es) Estereoisomeros de triciclodecan-9-il-xantogenato.
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
NO20091659L (no) Fremgangsmater for behandling av disruptive oppforselsforstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application